Ormidol (Atenolol)

Atenolol, the active ingredient in Ormidol, is a beta‑blocker presented as a tablet oral for oral use. It treats hypertension and angina in adults.

GNH USA supplies Ormidol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atenolol is a beta‑blocker used in cardiovascular disease management.

- Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. - Angina pectoris: decreases frequency and severity of chest pain episodes. - Cardiac arrhythmias: controls heart rate in supraventricular tachycardia. - Post‑myocardial infarction: improves long‑term survival and reduces recurrence risk.

Atenolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Fatigue or tiredness - Cold extremities (hands and feet) - Dizziness or light‑headedness - Headache - Bradycardia (slow heart rate) - Mild gastrointestinal upset (nausea, abdominal discomfort)

Serious or Rare Side Effects: - Severe bradycardia or heart block - Bronchospasm, especially in patients with asthma or COPD - Marked hypotension - Masking of hypoglycaemia symptoms in diabetic patients - Allergic reactions (rash, itching, angioedema) - Depression or mood changes

Before initiating Atenolol, consider the following safety measures.

- Blood pressure monitoring: ensure baseline measurements and regular follow‑up. - Cardiac function assessment: evaluate for existing conduction abnormalities. - Respiratory caution: avoid in uncontrolled asthma or severe COPD. - Renal impairment: dose adjustment may be required in reduced kidney function. - Discontinuation: taper gradually to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Atenolol can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Calcium‑channel blockers (verapamil, diltiazem): may cause excessive AV‑node depression. - Antidiabetic agents (insulin, sulfonylureas): risk of unrecognised hypoglycaemia. - Clonidine: abrupt withdrawal after Atenolol can precipitate severe hypertension.

Moderate Interactions (Monitor Closely): - NSAIDs: may attenuate antihypertensive effect. - Digoxin: increased serum levels leading to toxicity. - Selective serotonin reuptake inhibitors (SSRIs): potential additive bradycardia. - Non‑selective beta‑blockers: additive β‑blockade may enhance cardiac depression.